Considering that IFNα is FDA approved for the treatment of MF, along with its potent ability to activate cytotoxic cells in the context of antitumor immunity [35], led us to investigate whether IFNα could augment the benefits of CD47 blockade. The gene discussed is IFNA2; the disease is mycosis fungoides.